Press "Enter" to skip to content

Amgen’s New KRAS Inhibitor Is Found To Shrink Lung Tumors By 50%

Amgen Inc had its experimental drug proving helpful for almost half of the people dealing with an advanced form of lung cancer. The drug was found to attack the genetic driver of the disease that was earlier considered to be resistant to treatment. The drug named AMG 510 in its highest form was found to shrink tumors and also stabilize the disease in the patients. The drug was found to be effective in some patients while the rest were found to be resistant to it as well. The researchers have found a new technique to combat KRAS that is generally found in all the human tumors. The drug was found effective in 13% of non-small cell lung cancer patients.

The research team at Amgen is working on enhancing the response rate up to 50%. However, the study is still in its earlier days. The KRAS inhibitor was effective on a mutation is known as G12C and thus, made it a top competitor against Johnson & Johnson and Mirati Therapeutics Inc. The new product could help the company win the race and lower the dependency on older medications. The FDA has granted the drug a fast-track status for the metastatic non-small cell lung cancer patients having G12C mutation. Amgen is ready to kick start its next study for getting an approval.

The KRAS-targeting molecule is definitely a clear breakthrough for Amgen. Though the tumors are found to shrink, there are only a few percent chances that the patient lives longer. The medicine is hoped to have no toxicity effects or any drug-related side effects. Thus, the drug is eagerly awaited to hit the market. Similarly, the combination of low-dose, weight-based ipilimumab, and flat-dose nivolumab was found effective and safe as a first-line treatment in patients with stage IV non-small cell lung cancer. This nonrandomized CheckMate 817 study offered at International Association for the Study of Lung Cancer World Conference on Lung Cancer was conducted by Aix-Marseille University and Assistance Publique Hôpitaux de Marseille researchers. The study can help open a new door for the research in lung cancer.

Katina Elliot
Author Details

Katina Elliot is from a Health background and has completed a Degree in Microbiology before entering into the field of writing. Owing to her promising leadership and management skills, no doubt, Katina is the captain of the ship and heads the MRS News Blog’s Health section from last 3 years. With almost 5 years of experience in the writing industry, she is a versatile writer who can write on any topic in the Health sector such as latest inventions, research, new drugs, trials, and so on. By offering superior services, Katina has always helped the MRS News Blog platform to grow rapidly and reach the target audience and become one of the youngest and energetic leaders in the news sector.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *